Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an update.
Jiangsu Hengrui Pharmaceuticals has entered into a licensing agreement with Glenmark Specialty S.A. for its innovative drug, Trastuzumab Rezetecan, which targets HER2 mutations in non-small cell lung cancer. This agreement marks a significant step for Hengrui as it expands the reach of its self-developed drug, which was recently approved in China for treating advanced or metastatic NSCLC, enhancing its market positioning and potential impact on cancer treatment.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$94.54 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading pharmaceutical company in China, focusing on the development and production of innovative drugs. The company specializes in oncology, anesthesia, and imaging products, with a strong emphasis on research and development to address various medical needs.
Average Trading Volume: 5,638,524
Current Market Cap: HK$515.1B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.